113
168. Committee 2003 European Society of Hypertension – European Society of Cardi-
ology : guidelines for the management of arterial hypertension / J. Hypertens.
2003. – Vol. 21. – P. 1011-1053.
169. Effects of once-daily angiotensin-converting enzyme inhibition and calcium chan-
nel blockade-based antihypertensive treatment regimens on left ventricular hyper-
trophy and diastolic filling in hypertension. The Prospective Randomized Enalapril
Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial / R B.
Devereux, V. Palmieri, N. Sharpe et al. // Circulation. – 2001. – Vol. 104. – P.
1248-1254.
170. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvas-
cular complications in type 2 diabetes: UKPDS 39 / UK Prospective Diabetes
Study Group // BMJ. – 1998. – Vol. 317. – P. 713-720.
171. Legrand V. Стабильная стенокардия и ее лечение: все еще не решенная про-
блема в 2007 году. // Ишемическая болезнь сердца – научно-практический
анализ последних достижений в лечении ишемической болезни сердца № 3.
2007.
172. Fayers P.M., Hand D.J. Generalisation from phase III clinical trials: survival,
quavality of life, and healf economic// Lancet. – 1997. –Vol.350. –P.1025-1027.
173. Franklin S S. Cardiovascular risk evaluation an in exact science / S S. Franklin, N
D. Wong // J. Hypertens. – 2002. – Vol. 20. – P. 2127-2130.
174. Impact of coronary artery bypass grafting on various aspects of quality of life / H.
Sjoland, K. Caidahl, L. Wiklund et al. // Eur. J. Cardiothoracic Surg. – 1997. –
Vol. 12. – N. 4. – P. 612 – 619.
175. Grabam I, Atar D, Borcb-Jobnsen K et al. European guidelines on cardiovascular
disease prevention in clinical practice: executive summary. Eur Heart J 2007; 28:
2375-414.
176. Graban I, Atar D, Bordb-Jobnsen K et al.European guidelines on cardiovascular
diseas prevention in clinical practice: executive summary. Eur Heart J
2007;28:2375-414.
